Jump to main content
Jump to site search

Issue 7, 2017
Previous Article Next Article

Ruthenium-containing P450 inhibitors for dual enzyme inhibition and DNA damage

Author affiliations

Abstract

Cytochrome P450s are key players in drug metabolism, and overexpression in tumors is associated with significant resistance to many medicinal agents. Consequently, inhibition of P450s could serve as a strategy to restore drug efficacy. However, the widespread expression of P450s throughout the human body and the critical roles they play in various biosynthetic pathways motivates the development of P450 inhibitors capable of controlled local administration. Ruthenium complexes containing P450 inhibitors as ligands were synthesized in order to develop pro-drugs that can be triggered to release the inhibitors in a spatially and temporally controlled fashion. Upon light activation the compounds release ligands that directly bind and inhibit P450 enzymes, while the ruthenium center is able to directly damage DNA.

Graphical abstract: Ruthenium-containing P450 inhibitors for dual enzyme inhibition and DNA damage

Back to tab navigation

Supplementary files

Article information


Submitted
21 Nov 2016
Accepted
16 Jan 2017
First published
17 Jan 2017

Dalton Trans., 2017,46, 2165-2173
Article type
Paper

Ruthenium-containing P450 inhibitors for dual enzyme inhibition and DNA damage

A. Zamora, C. A. Denning, D. K. Heidary, E. Wachter, L. A. Nease, J. Ruiz and E. C. Glazer, Dalton Trans., 2017, 46, 2165
DOI: 10.1039/C6DT04405K

Social activity

Search articles by author

Spotlight

Advertisements